Loading
Metastasis and Carcinoma Case Studies / Lung Cancer Diagnosis and Treatment · Journal article
Orphanet Journal of Rare Diseases · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 60-year-old male with biphasic pulmonary blastoma treated with chemoradiotherapy and immunotherapy, combined with a 35-year bibliometric survey of 686 pulmonary blastoma publications and exploratory bioinformatic analysis of gene expression data implicating BMP signaling and the PI3K-Akt pathway. The study raises hypotheses about molecular mechanisms but does not provide validated diagnostic, prognostic, or therapeutic guidance beyond the clinical narrative of one patient.
Single case report integrated with bibliometric review and exploratory bioinformatic analysis. Single 60-year-old male with 40-pack-year smoking history presenting with cough and chest pain; confirmed biphasic pulmonary blastoma with mutant P53 and Ki-67 index approximately 70%; treated at an unspecified institution.. Intervention: Chemoradiotherapy followed by sintilimab (PD-1 inhibitor) immunotherapy; chemoradiotherapy discontinued due to myelosuppression.. Not stated; bibliometric analysis included global publications from 686 articles; United States (206), China, and Japan (49) identified as leading contributors; Washington University noted as most pr….
Clinical case: 60-year-old male with 40-pack-year smoking history, right upper lobe mass (15 × 9.8 cm) with pulmonary artery encasement and rib destruction; pathology confirmed biphasic PB with mutant P53 and Ki-67 index approximately 70%. Patient treated with chemoradiotherapy (discontinued due to myelosuppression) followed by sintilimab immunotherapy, with significant tumor shrinkage on follow-up CT. Bibliometric analysis retrieved 686 PB articles (1990–2025); United States (206 articles), China, and Japan (49 articles each) were leading contributors; 'mutations' emerged as recent research hotspot (burst strength 3.39, 2020–2025).
Patient treated with chemoradiotherapy (discontinued due to myelosuppression) followed by sintilimab immunotherapy, with significant tumor shrinkage on follow-up CT.
This case report and exploratory analysis suggests that BMP signaling and the PI3K-Akt pathway may be relevant to pulmonary blastoma biology, and documents one patient's response to immunotherapy after chemoradiotherapy failure. However, no validated diagnostic, prognostic, or therapeutic algorithm is established; findings require prospective validation in larger cohorts before clinical application.
A single case report integrated with bibliometric review and exploratory bioinformatic analysis of gene expression datasets; no clinical trial, no new diagnostic or therapeutic validation, and no quantitative evidence of intervention efficacy beyond one patient's response.
As stated by the source record.
Quoted from the source exactly as published.
This case report and exploratory analysis suggests that BMP signaling and the PI3K-Akt pathway may be relevant to pulmonary blastoma biology, and documents one patient's response to immunotherapy after chemoradiotherapy failure. However, no validated diagnostic, prognostic, or therapeutic algorithm is established; findings require prospective validation in larger cohorts before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Objective Pulmonary blastoma (PB) is a rare primary lung tumor, accounting for less than 0.5% of all lung cancers. Its epidemiological and clinical characteristics remain unclear, and the molecular pathogenesis had not been fully elucidated, which poses challenges to standardized diagnosis and treatment. This study aimed to: (1) summarize the clinical significance of PB (including epidemiology, clinical manifestations, diagnosis, treatment, and follow-up) through a case report; (2) systematically delineate the global research trends of PB over the past 35 years using bibliometric methods; (3) explore its molecular mechanisms via bioinformatics to provide evidence for clinical practice and research directions. Methods First, a detailed analysis of one PB case was conducted, documenting the patient’s demographic data (age, gender), progression of clinical symptoms, imaging findings, pathological characteristics, diagnostic workflow, treatment regimen, and follow-up outcomes. Second, for the bibliometric analysis, 686 PB-related articles published between 1990 and 2025 were retrieved from the Web of Science Core Collection. VOSviewer (version 1.6.20) was used to analyze author/institution collaboration networks and keyword co-occurrence patterns, while CiteSpace (version 6.2.R1) was employed to identify research frontiers and citation burst topics. Finally, to explore molecular mechanisms, PB-related gene expression datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were screened using the limma package with Benjamini–Hochberg FDR correction (screening threshold: |log₂FC| > 2, FDR < 0.05) (FDR = Benjamini–Hochberg adjusted P-value). Subsequently, Gene Ontology (GO) functional annotation, Reactome enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the clusterProfiler package. Results Clinical Case Presentation: A 60-year-old male with a 40‑pack‑year smoking history presented with cough and chest pain. Contrast‑enhanced chest CT revealed a lobulated mass (15 × 9.8 cm) in the right upper lobe, with encasement of the right pulmonary artery and osteolytic rib destruction. Pathological examination confirmed biphasic pulmonary blastoma (BPB), positive for mutant P53 and with a Ki‑67 index of approximately 70%. The patient received chemoradiotherapy, which was discontinued due to myelosuppression, followed by sintilimab immunotherapy. Follow‑up CT demonstrated significant tumor shrinkage. Bibliometric Analysis: A total of 686 PB‑related articles (1990–2025) were retrieved and analyzed, revealing five distinct developmental phases. The United States (206 articles), China, and Japan (49 articles each) were the leading contributors, with Washington University being the most productive institution. Research focus shifted over time from clinical‑pathological features to molecular mechanisms and congenital associations, with “cystic adenomatoid malformation” and “pathology” emerging as core thematic hotspots. Notably, the keyword 'mutations' (burst strength 3.39, 2020–2025) has become a recent research hotspot, which is highly consistent with the clinical demand for molecular targeted therapy of PB in this study. Bioinformatic Investigation: Analysis of the GSE110205 dataset identified 6782 DEGs. Intersection with known PB‑associated genes yielded 34 overlapping genes. GO enrichment analysis highlighted BMP signaling involvement, while KEGG pathway analysis prioritized the PI3K‑Akt pathway. Reactome pathway enrichment further indicated significant associations with growth factor signal transduction and surfactant metabolism. Conclusion This study constructed an integrated "clinical case-bibliometrics-bioinformatics" framework for PB. Clinical findings clarified PB’s imaging, pathological, and therapeutic characteristics; bibliometrics mapped global research trends; bioinformatics identified BMP signaling and PI3K-Akt pathway as core drivers. These results optimize PB’s early diagnosis and provide theoretical support for personalized intervention.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.